Chimerix — Cowen Healthcare Conference 2019
20 slides from Chimerix's conference presentation, Mar 11, 2019

Slide 1: Cowen Healthcare Conference
COWEN HEALTHCARE CONFERENCE TIMOTHY W. TROST CHIEF FINANCIAL OFFICER MARCH 11, 2019

Slide 2: Forward-Looking Statements
2 Forward - Looking Statements These slides and the accompanying oral presentation contain forward - looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility tha

Slide 3: CMRX: Developing Solutions for Immunocompromised Patients
CMRX: Developing Solutions for Immunocompromised Patients ▪ The Team : Experienced and committed management team with proven track records developing first - in - class antivirals and first - in - indication commercial launches ▪ The Molecule : Brincidofovir (BCV, CMX001) remains the only broad - sp

Slide 4: BCV Has Broad Spectrum Activity and High Potency
BCV Has Broad Spectrum Activity and High Potency: Results from a Systematic Literature Review 4 Chemaly RF et al. Antiviral Res. 2019 Mar;163:50 - 58. GN138

Slide 5: Brincidofovir's Broad Spectrum Provides a Potential Pipeline in a Product
5 Brincidofovir’s Broad Spectrum of Activity Provides a Potential “Pipeline in a Product” with Patent Protection Through 2034 ▪ Oral BCV for Adenovirus : □ potent antiviral activity retained across all AdV types □ rapid reduction in AdV viral load □ first prospectively randomized trial ▪ Oral BCV fo

Slide 6: AdAPT: Adenovirus after Allogeneic Pediatric Transplantation
Follow up Period Potential Treatment Period Potential Treatment Period 6 AdAPT: Adenovirus after Allogeneic Pediatric Transplantation ▪ Open label, comparative study of oral BCV vs. standard of care (SoC) in AdV viremia – Pediatric T - cell depleted allo - HCT recipients in 1 st 100 days of HCT with

Slide 7: Calculating AdV Average Viral Burden = AdV AAUC
7 Calculating AdV Average Viral Burden = AdV AAUC 0 - 16 AdV viremia (copies/mL) 1000 Day 0 Week 16 + + + + + + + + + + Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 Wk 6 Wk 7 Wk 8 Wk 9 Wk 11 Wk 10 16 AdV AUC AdV AAUC

Slide 8: Higher AdV AUC Correlates with Higher Mortality
8 Higher AdV AUC 0 - 16 Correlates with Higher Mortality Days from First AdV viremia ≥1000 copies/mL AAUC 1st quartile AAUC 2nd quartile AAUC 3rd quartile AAUC 4th quartile Undetectable 100 10,000 1,000,000 100,000,000 10,000,000,000 0 14 28 42 56 70 84 98 112 0 14 28 42 56 70 84 98 112 0 14 28 42 5

Slide 9: AdAPT Is Designed for Success
- 4 12 16 WEEK 4 2 0 8 9 AdAPT Is Designed for Success * Local standard - of - care may include reduction of immunosuppressants or off - label IV cidofovir † Lower limit of detection: 2 log 10 copies/mL [AdV AAUC for local SOC] – [AdV AAUC with BCV] = potential difference in AdAPT [4.40] – [2.03] =

Slide 10: Maximizing the Probability of Success for AdAPT
10 Maximizing the Probability of Success for AdAPT ▪ Study design incorporates key learnings for oral brincidofovir: – Includes highest risk patients: pediatric recipients of T - cell depleted HCT prior to immune reconstitution – Short - course oral BCV therapy begun as soon as feasible as feasible

Slide 11: Status of FDA Discussions on AdAPT
11 Status of FDA Discussions on AdAPT ▪ Type C Meeting Requested to review data supporting use of AdV AAUC as a surrogate marker – AdVance data and other independent studies demonstrate AdV AAUC correlation with mortality – Briefing Package submitted to FDA in late February – FDA response received o

Slide 12: Adenovirus Increasingly Recognized in Community Outbreaks
12 Adenovirus Increasingly Recognized in Community Outbreaks ▪ Highly pathogenic strains of AdV have been reported in otherwise healthy adults and children ▪ Relatively immunocompromised patients may be at increased risk of fatal outcomes ▪ Extrapolation from viral panels and known community pneumon

Slide 13: Building Value for Oral and IV Brincidofovir: Land and Expand
13 Building Value for Oral and IV Brincidofovir: “Land and Expand” Pediatric & Adult Allo - HCT Recipients: AdV Treatment Pediatric & Adult HCT and SOT Recipients: AdV Treatment Immunocompromised AdV Patients: AdV Treatment Treatment for Hospitalized AdV Patients EXPAND Via Lifecycle Management & Cl

Slide 14: IV BCV: Fulfilling the Potential for Prevention and Treatment
14 IV BCV: Fulfilling the Potential for Prevention and Treatment Early development work shows great promise for IV BCV Delivers uniform exposure Delivers drug to difficult - to - reach compartments, especially the brain Convenience with improved tolerability Animal data predict improved tolerability

Slide 15: IV BCV: Multiple Dose Study Demonstrates Improved Tolerability
15 IV BCV: Multiple Dose Study Demonstrates Improved Tolerability ▪ IV BCV x 4 doses in healthy adult subjects (Multiple Ascending Dose study) – Confirmed IV BCV 10 mg achieves exposure of oral BCV 100 mg – No diarrhea at 10 mg twice weekly – No dose - limiting clinical adverse events ▪ Phase 2 pati

Slide 16: IV BCV for Prevention: High Risk of Disease or Death
16 IV BCV for Prevention: High Risk of Disease or Death from New or Reactivated Viruses in Stem Cell Transplant Recipients At least one DNA Virus in 363/404= 90% 2/3 have two or more DNA viruses 66% 1 in 3 HCT recipients had ≥3 DNA viral infections detected Hill JA et al. Blood. 2017;129(16):2316 -

Slide 17: Oral and IV BCV Address Growing Opportunities in Transplantation
17 Oral and IV BCV May Address Growing Opportunities to Address Viral Infections in Stem Cell and Solid Organ Transplantation TRANSPLANTS PER YEAR (population) US (320M) EU (550M) Japan (130M) ROW Total HCT Allogeneic 8,700 16,400 3,700 6,454 35,254 Autologous 15,000 21,700 1,800 4,715 43,215 HCT TO

Slide 18: BCV for Smallpox: Nearing Completion of Animal Studies
18 BCV for Smallpox: Nearing Completion of Animal Studies Under Development with BARDA ▪ Oral BCV has demonstrated substantial survival benefit in two animal models of fatal orthopoxvirus infections: 1. Rabbitpox virus model: Two studies completed with 100% survival demonstrated in animals that rece

Slide 19: Second Rabbitpox Study Shows Significant Survival Advantage
19 Second Rabbitpox Study Shows Significant Survival Advantage in Animals Treated with BCV ▪ The study was designed to determine the effect of administering BCV to animals at certain times (3, 4, 5 or 6 days) after inoculation with the rabbitpox virus Preliminary/Unaudited Results BCV treatment 3 da

Slide 20: CMRX: Four Active Clinical Programs in 2019
20 CMRX: Four Active Clinical Programs in 2019 Program Indication Pre - clinical Phase 1 Phase 2 Phase 3 Status Short - course Oral BCV AdV Treatment Smallpox Treatment AdAPT enrolling Animal Rule Pivotal Studies Progressing IV BCV Other Viral Indications Ph 2 trials initiated ▪ Brincidofovir repres
Source: SEC EDGAR · 8-K filed Mar 11, 2019
More decks from Chimerix Inc
Investor Presentation (December 2024)39 slides · Dec 10, 2024
Investor Presentation (November 2024)35 slides · Nov 7, 2024
Investor Presentation (August 2024)35 slides · Aug 13, 2024
Investor Presentation (May 2024)29 slides · May 1, 2024
Investor Presentation (February 2024)29 slides · Feb 29, 2024
Investor Presentation (November 2023)42 slides · Nov 2, 2023